Equity Profile

NTRA

NATERA INC

Health CareBiotechnology$30.8B

Aug6Thu

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Natera Inc (NTRA) is a biotechnology company focused on genetic testing and diagnostics, particularly in prenatal and oncology settings. With a market cap of $31 billion, it plays a significant role in the healthcare sector, addressing the growing demand for personalized medicine and genetic insights.

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of profitability and will help gauge whether Natera is moving closer to profitability or facing continued losses.

N/A

Revenue Growth

Revenue growth is crucial to understanding the company's market traction and demand for its genetic testing services.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

NTRA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-25.11%

Avg Stock Reaction

+1.61%

Last Quarter Recap

In Q1-2026, Natera reported an EPS of -$0.60, which was worse than the expected -$0.53. The stock reacted positively, gaining 2.20% the following day, despite the miss.

Management Promises & Guidance

Focus on expanding test offerings in oncology.
Commitment to improving operational efficiency.
Plans to enhance customer engagement and support.

Expectations

Wall Street Expectations

Overall, expectations for Natera's upcoming earnings are mixed, with no clear consensus on profitability or revenue growth. Investors are keenly watching for any signs of improvement in key metrics.

Bull Case

If Natera can demonstrate significant revenue growth and a reduction in losses, it could bolster investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to show progress in its financials or operational metrics, it may lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected test volume for the upcoming quarter?

Test volume is a direct indicator of demand for Natera's services and will be critical in assessing revenue growth potential.

Will there be any updates on the company's path to profitability?

Investors are eager to hear about any strategies or timelines that could lead to improved financial performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for revenue growth driven by new test offerings, which could significantly impact the bottom line.

Supporting Evidence

Natera has a history of surprising analysts with better-than-expected test volumes.

Recent insider selling may indicate a lack of confidence in near-term performance, contrasting with potential growth narratives.

The options market is pricing a larger move than historical averages suggest, indicating potential mispricing.

Key Risk

If test volumes exceed expectations, it could invalidate the cautious outlook currently held by analysts.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Natera can show progress in both revenue growth and a path to profitability.

Bull Confirmed If

Demonstrating a revenue growth rate of at least 15% quarter-over-quarter would confirm the bull case.

Bear Confirmed If

If the EPS loss exceeds -$0.70, it would reinforce the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±14.15%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±14.2% while NTRA has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

60.3%

Calls (19K)P/C Ratio: 0.17Puts (226K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$299,440.95

1,500 sh

1 insider

Net

$299,440.95

Net selling

Most Active Insiders· 2 open-market trades

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Natera beats expectations and raises guidance, history suggests the stock could rise by around 1.81%, confirming a positive outlook.

In-Line / Cautious

If results are in line with cautious commentary, the stock may experience muted movement as investors reassess their expectations.

Miss

A miss on earnings could lead to a decline of about 1.41%, as seen in past quarters, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new test offerings and their expected impact on revenue.
2Any commentary on operational improvements and cost management.
3Insights into customer engagement strategies and market expansion.
4Details on the timeline for achieving profitability.
5Feedback from key partnerships or collaborations.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Danaos Corporation

Company Snapshot

Key Metrics to Watch

EPS (Earnings Per Share)

EPS is a key indicator of profitability and will help gauge whether Natera is moving closer to profitability or facing continued losses.

N/A

Revenue Growth

Revenue growth is crucial to understanding the company's market traction and demand for its genetic testing services.

N/A

1 more metrics, Wall Street expectations, options signals, track record, and call prep available with Pro.

NTRA Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

50%

Avg EPS Surprise

-25.11%

Avg Stock Reaction

+1.61%

Last Quarter Recap

In Q1-2026, Natera reported an EPS of -$0.60, which was worse than the expected -$0.53. The stock reacted positively, gaining 2.20% the following day, despite the miss.

Management Promises & Guidance

Focus on expanding test offerings in oncology.
Commitment to improving operational efficiency.
Plans to enhance customer engagement and support.

Expectations

Wall Street Expectations

Overall, expectations for Natera's upcoming earnings are mixed, with no clear consensus on profitability or revenue growth. Investors are keenly watching for any signs of improvement in key metrics.

Bull Case

If Natera can demonstrate significant revenue growth and a reduction in losses, it could bolster investor confidence and drive the stock higher.

Bear Case

Conversely, if the company fails to show progress in its financials or operational metrics, it may lead to further declines in stock price.

Expectations

Two Questions That Matter

The print will turn on these two things.

What is the expected test volume for the upcoming quarter?

Test volume is a direct indicator of demand for Natera's services and will be critical in assessing revenue growth potential.

Will there be any updates on the company's path to profitability?

Investors are eager to hear about any strategies or timelines that could lead to improved financial performance.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for revenue growth driven by new test offerings, which could significantly impact the bottom line.

Supporting Evidence

Natera has a history of surprising analysts with better-than-expected test volumes.

Recent insider selling may indicate a lack of confidence in near-term performance, contrasting with potential growth narratives.

The options market is pricing a larger move than historical averages suggest, indicating potential mispricing.

Key Risk

If test volumes exceed expectations, it could invalidate the cautious outlook currently held by analysts.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The core debate this quarter revolves around whether Natera can show progress in both revenue growth and a path to profitability.

Bull Confirmed If

Demonstrating a revenue growth rate of at least 15% quarter-over-quarter would confirm the bull case.

Bear Confirmed If

If the EPS loss exceeds -$0.70, it would reinforce the bear case.

Pre-Earnings Positioning

Options Market

Implied Move

±14.15%

Historical Avg

±2.4%

Pricing rich

The options market is pricing in a significant move, indicating that traders expect volatility around the earnings report.

Options are pricing ±14.2% while NTRA has averaged ±2.4% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.6%

30d HV

60.3%

Calls (19K)P/C Ratio: 0.17Puts (226K)

Edge

Insider Activity

Open-market trades by officers, directors, and 10%+ holders over the trailing 90 days.

Bought

$0.00

0 sh

0 insiders

Sold

$299,440.95

1,500 sh

1 insider

Net

$299,440.95

Net selling

Most Active Insiders· 2 open-market trades

Insider

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Natera beats expectations and raises guidance, history suggests the stock could rise by around 1.81%, confirming a positive outlook.

In-Line / Cautious

If results are in line with cautious commentary, the stock may experience muted movement as investors reassess their expectations.

Miss

A miss on earnings could lead to a decline of about 1.41%, as seen in past quarters, reflecting investor disappointment.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Updates on new test offerings and their expected impact on revenue.
2Any commentary on operational improvements and cost management.
3Insights into customer engagement strategies and market expansion.
4Details on the timeline for achieving profitability.
5Feedback from key partnerships or collaborations.